July 2, 2020

Volume X, Number 184

July 01, 2020

Subscribe to Latest Legal News and Analysis

June 30, 2020

Subscribe to Latest Legal News and Analysis

June 29, 2020

Subscribe to Latest Legal News and Analysis

THE LATEST: Health Care Antitrust Enforcement Remains a Top Priority for New FTC Commissioners

On April 27, 2018, the United States Senate confirmed President Trump’s five nominees for Commissioners of the Federal Trade Commission (FTC). Three are Republicans: Chairman Joseph Simons, Noah Phillips and Christine Wilson, and two are Democrats: Rohit Chopra and Rebecca Slaughter. The Senate’s vote returns the FTC to a full complement of Commissioners for the first time under the Trump Administration. Of note to participants in the health care sector: the FTC shares civil antitrust law enforcement jurisdiction over the health care industry with the Department of Justice Antitrust Division, but takes the lead when it comes to the health care provider, pharmaceutical and medical device industries.

FTC Antitrust Enforcement in Health Care Will Likely Remain Robust

It is very unlikely that President Trump’s newly confirmed FTC Commissioners will usher in a period of more lax antitrust enforcement at the FTC, including in health care. For example, during a February 14, 2018, Senate confirmation hearing on four of President Trump’s nominees to serve as FTC Commissioners, each of them testified that antitrust enforcement in the health care sector will remain a top priority of the Commission.

  • Chairman, Joseph Simons (R): “Americans are hearing more about antitrust, seeing high health care costs . . . . I am here before you because if confirmed I want to help lead the FTC at this critical time.”
  • Christine Wilson (R): If confirmed, she anticipates “spending a great deal of time and effort” to “ensuring competition in healthcare markets.” Ms. Wilson will not take her seat until the Senate votes on current Chairman Maureen Ohlhausen’s nomination to the US Court of Federal Claims.
  • Noah Phillips (R): The FTC “has a proud, decades-long…record… to keep competition going in healthcare markets, from reviewing mergers of hospitals, to policing prescription drug prices. If confirmed, I look forward to working to make that issue a priority.”
  • Rohit Chopra (D): “It must be a top priority to enforce all the applicable laws” in the health care and pharmaceutical markets. (After this hearing, on March 26, 2018, President Trump nominated Rebecca Slaughter [D] for the remaining Commissioner vacancy.)

Is Past Prologue: The Presumptive New Chairman’s Prior Tenure at the FTC

These views are underscored by the track record of Joseph Simons, President Trump’s nominee for Chairman. Simons served from 2001-03 as the Director of the Bureau of Competition at the FTC, during the administration of President George W. Bush. During that stint, Simons led the Bureau’s merger and non-merger antitrust law enforcement efforts and brought a record number of civil actions against health care providers. Here are some highlights from Simon’s prior tenure at the FTC:

  • Creation of the Hospital Merger Litigation Task Force
    • Led to the creation of the Mergers IV division, which reviews health care provider mergers and acquisitions.
    • Announced a “hospital merger retrospective” to analyze what happened to prices and purported efficiencies after recently consummated hospital mergers. This study led to a formal investigation in 2003 and complaint in 2004 concerning a merger that was consummated in 2000.
  •  Renewed Focus on Administrative Litigation
    • Significantly increased the number of administrative trials, including merger, price-fixing and monopolization cases.
  • Reinvigoration of FTC’s Non-Merger Enforcement Program
    • Initiated more than 100 non-merger enforcement investigations.
    • Broke a 20-year-old record for non-merger enforcement actions performed in a single year.
    • Concluded at least 13 physician group price-fixing consent decrees, with several completed shortly thereafter. 
  • Continued FTC Enforcement Efforts in the Pharmaceutical Industry
    • Pursued investigations and consent orders regarding what are now called “pay-for-delay” agreements between branded and generic drug competitors, while also litigating In the Matter of Schering-Plough, which had its origins under Simons’ predecessor.
    • Took actions against pharmaceutical companies for allegedly misusing US Food and Drug Administration (FDA) processes for the purpose of delaying market entry of generic competition.
    • Brought five enforcement actions resulting in divestitures through consent agreement.

The Takeaway

With the unusual opportunity to nominate every FTC Commissioner taking his or her seat more or less at the same time, President Trump has populated the Commission with officials who have indicated that health care antitrust enforcement will remain a top priority for the agency. Industry participants should therefore expect no let-up in the scrutiny that the FTC places on health care providers and pharmaceutical companies when they engage in mergers and acquisitions or in conduct that is susceptible to concerns about anticompetitive effects.

© 2020 McDermott Will & EmeryNational Law Review, Volume VIII, Number 124


About this Author

Jeffrey W. Brennan, McDermott Will Emery Law Firm, Antitrust Attorney

Jeffrey W. Brennan is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm’s Washington, D.C., office.  He focuses his practice on mergers, litigation, government investigations and counseling, with extensive experience across a broad range of industries, including the health care sector. 


Stephen Wu is a partner in the law firm of McDermott Will & Emery and is based in the Firm’s Chicago office. He focuses his practice on complex litigation, mergers and acquisitions, and counseling clients on pricing and distribution issues. Stephen has represented clients in a wide variety of industries including: aerospace, biotechnology, consumer products, energy, food, and health care.

Stephen has defended clients in private litigation against federal and state antitrust and unfair competition claims, and represented clients in criminal antitrust investigations. For mergers and acquisitions, Stephen has defended transactions before the United States Department of Justice and the Federal Trade Commission. Besides pricing and distribution issues, Stephen has also counseled clients on standards-setting and compliance with consumer protection laws.

Prior to joining the Firm, Stephen was an attorney for the Federal Trade Commission (FTC), where he participated in all aspects of the FTC’s merger enforcement program, from investigating multibillion dollar transactions to negotiating consent orders resolving the government’s competition concerns. At the FTC, he received an Award for Meritorious Service and its Stephen Nye Award, the FTC’s highest award given to a junior attorney, in 2001.

Stephen Vaughn, Mcdermott, Antitrust lawyer

Steven Vaughn focuses his practice on antitrust litigation and class action defense. Steven has a strong background in economics and both civil and criminal government investigations. 

During law school, Steven served as a law clerk for the US Senate Permanent Subcommittee on Investigations, and as an intern for Hon. Barbara A. McAuliffe in the United States District Court for the Eastern District of California. Steven was Senior Articles Editor for the Georgetown Journal of Law & Public Policy, and an executive board member of the Georgetown Chapter of The...

312 984 2726